APLS FY 2024 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$781M+97.0% YoY

Gross Profit

$664M84.9% margin

Operating Income

-$165M-21.1% margin

Net Income

-$198M-25.3% margin

EPS (Diluted)

$-1.60

Cash Flow

Operating Cash Flow

-$88M

Free Cash Flow

-$88M

Stock-Based Comp.

$114M

Balance Sheet

Total Assets

$885M

Total Liabilities

$657M

Stockholders' Equity

$229M

Cash & Equivalents

$411M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$781M	$397M	+97.0%
Gross Profit	$664M	$338M	+96.3%
Operating Income	-$165M	-$517M	+68.1%
Net Income	-$198M	-$529M	+62.6%